Imagine being told you have prostate cancer, a disease that affects tens of thousands of men every year, only to discover a groundbreaking trial that could change everything. This is exactly what happened to Willy Goldschmidt, a Coventry resident whose story is both inspiring and eye-opening.
Prostate cancer is the most common cancer among men, with over 55,000 diagnoses in the UK annually. While it’s curable if caught early, the treatment journey can be daunting. Traditionally, patients undergo 20 days of radiotherapy spread over four weeks. But here’s where it gets controversial: What if the same results could be achieved in just five days? That’s precisely what the Pace B trial set out to prove—and it succeeded.
Led by The Royal Marsden and involving over 870 patients worldwide, including participants from Coventry and Warwickshire, the trial tested Stereotactic Body Radiotherapy (SBRT). This approach delivers higher, targeted doses of radiation over five days. After five years, the results were staggering: 96% of men who received SBRT were cancer-free, compared to 95% on standard treatment. While the difference might seem small, it’s a game-changer for treatment efficiency and patient convenience.
For Willy Goldschmidt, diagnosed in 2017, the condensed two-week treatment schedule at University Hospital Coventry and Warwickshire was a no-brainer. He opted for radiotherapy over surgery and was randomly selected for the SBRT arm of the trial. And this is the part most people miss: His experience wasn’t just about beating cancer—it was about gaining a new perspective on life. “The treatment and follow-up monitoring have been life-changing,” he said. “It removed any concerns I had about this potentially lethal disease.”
Today, SBRT is the standard treatment for men with low to low-intermediate risk prostate cancer at University Hospitals Coventry and Warwickshire NHS Trust. Consultant Clinical Oncologist Dr. Andrew Chan emphasizes its impact: “We now have evidence to support higher doses over a shorter time, and patients are benefiting tremendously.”
Goldschmidt’s journey has inspired him to become a research champion for the trust, advocating for others to participate in trials. “I feel privileged to have been part of something that could transform prostate cancer treatment for countless others,” he shared.
But here’s the thought-provoking question: If shorter, more efficient treatments like SBRT become the norm, how might this shift the way we approach cancer care globally? Could this model be applied to other cancers? We’d love to hear your thoughts in the comments.
If you’re in Warwickshire and have a story you think we should cover, get in touch. Let’s keep the conversation going and continue to shed light on innovations that save lives.
